BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61. [PMID: 20164691 DOI: 10.1097/PPO.0b013e3181d24ff7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 109] [Article Influence: 16.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Pandya P, Afshar S. Therapeutic Advances in Oncology. Int J Mol Sci 2021;22:2008. [PMID: 33670524 DOI: 10.3390/ijms22042008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Yip C, Foidart P, Somja J, Truong A, Lienard M, Feyereisen E, Schroeder H, Gofflot S, Donneau AF, Collignon J, Delvenne P, Sounni NE, Jerusalem G, Noël A. MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. Br J Cancer 2017;116:742-51. [PMID: 28196064 DOI: 10.1038/bjc.2017.23] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
3 Mustacchi G, De Laurentiis M. The role of taxanes in triple-negative breast cancer: literature review. Drug Des Devel Ther 2015;9:4303-18. [PMID: 26273192 DOI: 10.2147/DDDT.S86105] [Cited by in Crossref: 61] [Cited by in F6Publishing: 39] [Article Influence: 10.2] [Reference Citation Analysis]
4 Misra S, Zhang X, Wani NA, Sizemore S, Ray A. Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment. Oncotarget 2020;11:784-800. [PMID: 32166000 DOI: 10.18632/oncotarget.27485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 He JX, Yang CH, Miao ZH. Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol Sin 2010;31:1172-80. [PMID: 20676117 DOI: 10.1038/aps.2010.103] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
6 Kwon A, Lee GB, Park T, Lee JH, Ko P, You E, Ahn JH, Eom SH, Rhee S, Song WK. Potent Small-Molecule Inhibitors Targeting Acetylated Microtubules as Anticancer Agents Against Triple-Negative Breast Cancer. Biomedicines 2020;8:E338. [PMID: 32917017 DOI: 10.3390/biomedicines8090338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Castrellon AB, Pidhorecky I, Valero V, Raez LE. The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer. Oncol Rev 2017;11:324. [PMID: 28382189 DOI: 10.4081/oncol.2017.324] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
8 Kasimir-Bauer S, Keup C, Hoffmann O, Hauch S, Kimmig R, Bittner AK. Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer. Front Oncol 2020;10:1658. [PMID: 33014830 DOI: 10.3389/fonc.2020.01658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yuan X, Kho D, Xu J, Gajan A, Wu K, Wu GS. ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells. Oncotarget 2017;8:21626-38. [PMID: 28423492 DOI: 10.18632/oncotarget.15451] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
10 AiErken N, Shi HJ, Zhou Y, Shao N, Zhang J, Shi Y, Yuan ZY, Lin Y. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. Int J Biol Sci 2017;13:1172-9. [PMID: 29104508 DOI: 10.7150/ijbs.20868] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
11 Hsieh CH, Chao KS, Liao HF, Chen YJ. Norcantharidin, derivative of cantharidin, for cancer stem cells. Evid Based Complement Alternat Med 2013;2013:838651. [PMID: 24073010 DOI: 10.1155/2013/838651] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
12 Li Y, Liang Y, Sang Y, Song X, Zhang H, Liu Y, Jiang L, Yang Q. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis 2018;9:14. [PMID: 29323124 DOI: 10.1038/s41419-017-0030-7] [Cited by in Crossref: 48] [Cited by in F6Publishing: 58] [Article Influence: 16.0] [Reference Citation Analysis]
13 Kamalabadi-Farahani M, H Najafabadi MR, Jabbarpour Z. Apoptotic Resistance of Metastatic Tumor Cells in Triple Negative Breast Cancer: Roles of Death Receptor-5. Asian Pac J Cancer Prev 2019;20:1743-8. [PMID: 31244295 DOI: 10.31557/APJCP.2019.20.6.1743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chou HH, Kuo WL, Yu CC, Tsai HP, Shen SC, Chu CH, Yu MC, Lo YF, Dabora MA, Chang HK, Lin YC, Ueng SH, Chen SC. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy. Biomed J 2019;42:66-74. [PMID: 30987708 DOI: 10.1016/j.bj.2018.10.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
15 Sultan M, Nearing JT, Brown JM, Huynh TT, Cruickshank BM, Lamoureaux E, Vidovic D, Dahn ML, Fernando W, Coyle KM, Giacomantonio CA, Langille MGI, Marcato P. An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer. Mol Oncol 2021;15:2046-64. [PMID: 33932086 DOI: 10.1002/1878-0261.12964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Alsaleem MA, Ball G, Toss MS, Raafat S, Aleskandarany M, Joseph C, Ogden A, Bhattarai S, Rida PCG, Khani F, Davis M, Elemento O, Aneja R, Ellis IO, Green A, Mongan NP, Rakha E. A novel prognostic two-gene signature for triple negative breast cancer. Mod Pathol 2020;33:2208-20. [PMID: 32404959 DOI: 10.1038/s41379-020-0563-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
17 He DX, Wu XL, Lu CX, Gu XT, Zhang GY, Ma X, Liu DQ. Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer. Oncol Rep 2017;38:3392-402. [PMID: 29039577 DOI: 10.3892/or.2017.6033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Naik A, Al-Yahyaee A, Abdullah N, Sam JE, Al-Zeheimi N, Yaish MW, Adham SA. Neuropilin-1 promotes the oncogenic Tenascin-C/integrin β3 pathway and modulates chemoresistance in breast cancer cells. BMC Cancer 2018;18:533. [PMID: 29728077 DOI: 10.1186/s12885-018-4446-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
19 Pham TH, Park HM, Kim J, Hong JT, Yoon DY. Interleukin-32θ Triggers Cellular Senescence and Reduces Sensitivity to Doxorubicin-Mediated Cytotoxicity in MDA-MB-231 Cells. Int J Mol Sci 2021;22:4974. [PMID: 34067074 DOI: 10.3390/ijms22094974] [Reference Citation Analysis]
20 Shao Z, Chaudhri S, Guo M, Zhang L, Rea D. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study. Oncol Res 2016;23:291-302. [PMID: 27131315 DOI: 10.3727/096504016X14562725373879] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
21 Kudo M, Zalles N, Distefano R, Nigita G, Veneziano D, Gasparini P, Croce CM. Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells. Cell Death Differ 2021. [PMID: 34561554 DOI: 10.1038/s41418-021-00864-2] [Reference Citation Analysis]
22 Siddique AB, Ayoub NM, Tajmim A, Meyer SA, Hill RA, El Sayed KA. (-)-Oleocanthal Prevents Breast Cancer Locoregional Recurrence After Primary Tumor Surgical Excision and Neoadjuvant Targeted Therapy in Orthotopic Nude Mouse Models. Cancers (Basel) 2019;11:E637. [PMID: 31072015 DOI: 10.3390/cancers11050637] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
23 Jiang C, Wang X, Teng B, Wang Z, Li F, Zhao Y, Guo Y, Zeng Q. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer. ACS Appl Mater Interfaces 2021;13:35248-65. [PMID: 34284582 DOI: 10.1021/acsami.1c02074] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Varghese E, Samuel SM, Varghese S, Cheema S, Mamtani R, Büsselberg D. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells. Biomolecules 2018;8:E163. [PMID: 30563138 DOI: 10.3390/biom8040163] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
25 Nam K, Son SH, Oh S, Jeon D, Kim H, Noh DY, Kim S, Shin I. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells. Oncotarget 2017;8:35804-23. [PMID: 28415760 DOI: 10.18632/oncotarget.16208] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
26 Doğukan R, Uçak R, Doğukan FM, Tanık C, Çitgez B, Kabukcuoğlu F. Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients. Eur J Breast Health 2019;15:235-41. [PMID: 31620682 DOI: 10.5152/ejbh.2019.4912] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
27 Banerjee D. Reinventing diagnostics for personalized therapy in oncology. Cancers (Basel) 2010;2:1066-91. [PMID: 24281107 DOI: 10.3390/cancers2021066] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
28 Lee JO, Kang MJ, Byun WS, Kim SA, Seo IH, Han JA, Moon JW, Kim JH, Kim SJ, Lee EJ, In Park S, Park SH, Kim HS. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51. Breast Cancer Res 2019;21:115. [PMID: 31640742 DOI: 10.1186/s13058-019-1204-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
29 Manjunath M, Choudhary B. Triple-negative breast cancer: A run-through of features, classification and current therapies. Oncol Lett 2021;22:512. [PMID: 33986872 DOI: 10.3892/ol.2021.12773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, Carasi S, Palmieri D, Costinean S, Shapiro CL. Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci USA. 2014;111:4536-4541. [PMID: 24616504 DOI: 10.1073/pnas.1402604111] [Cited by in Crossref: 120] [Cited by in F6Publishing: 118] [Article Influence: 17.1] [Reference Citation Analysis]
31 Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010;3:42. [PMID: 20979652 DOI: 10.1186/1756-8722-3-42] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
32 Ye J, Xia X, Dong W, Hao H, Meng L, Yang Y, Wang R, Lyu Y, Liu Y. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines. Int J Nanomedicine 2016;11:4125-40. [PMID: 27601899 DOI: 10.2147/IJN.S113638] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
33 Chen D, Ma Y, Guo Z, Liu L, Yang Y, Wang Y, Pan B, Wu L, Hui Y, Yang W. Two Natural Alkaloids Synergistically Induce Apoptosis in Breast Cancer Cells by Inhibiting STAT3 Activation. Molecules 2020;25:E216. [PMID: 31948057 DOI: 10.3390/molecules25010216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
34 Nakajima W, Miyazaki K, Asano Y, Kubota S, Tanaka N. Krüppel-Like Factor 4 and Its Activator APTO-253 Induce NOXA-Mediated, p53-Independent Apoptosis in Triple-Negative Breast Cancer Cells. Genes (Basel) 2021;12:539. [PMID: 33918002 DOI: 10.3390/genes12040539] [Reference Citation Analysis]
35 Tečić Vuger A, Šeparović R, Vazdar L, Pavlović M, Lepetić P, Šitić S, Bajić Ž, Šarčević B, Vrbanec D. CHARACTERISTICS AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS: A CROATIAN SINGLE INstitution RETROSPECTIVE COHORT STUDY. Acta Clin Croat 2020;59:97-108. [PMID: 32724280 DOI: 10.20471/acc.2020.59.01.12] [Reference Citation Analysis]
36 Ribnikar D, Ribeiro JM, Pinto D, Sousa B, Pinto AC, Gomes E, Moser EC, Cardoso MJ, Cardoso F. Breast cancer under age 40: a different approach. Curr Treat Options Oncol. 2015;16:16. [PMID: 25796377 DOI: 10.1007/s11864-015-0334-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
37 Morante Z, Ruiz R, Araujo JM, Pinto JA, Cruz-Ku G, Urrunaga-Pastor D, Namuche F, Flores C, Mantilla R, Luján MG, Fuentes H, Schwarz L, Aguilar A, Neciosup S, Gómez HL. Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer. Clin Breast Cancer 2021;21:239-246.e4. [PMID: 33221201 DOI: 10.1016/j.clbc.2020.09.008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Montero A, Glück S. Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer. Case Rep Oncol 2012;5:687-92. [PMID: 23341813 DOI: 10.1159/000346345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
39 Subramaniam D, Thombre R, Dhar A, Anant S. DNA Methyltransferases: A Novel Target for Prevention and Therapy. Front Oncol. 2014;4:80. [PMID: 24822169 DOI: 10.3389/fonc.2014.00080] [Cited by in Crossref: 252] [Cited by in F6Publishing: 223] [Article Influence: 36.0] [Reference Citation Analysis]
40 Lazarus G, Audrey J, Iskandar AWB. Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review. Oncol Rev 2019;13:425. [PMID: 31857857 DOI: 10.4081/oncol.2019.425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Abumanhal-Masarweh H, da Silva D, Poley M, Zinger A, Goldman E, Krinsky N, Kleiner R, Shenbach G, Schroeder JE, Shklover J, Shainsky-Roitman J, Schroeder A. Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells. J Control Release 2019;307:331-41. [PMID: 31238049 DOI: 10.1016/j.jconrel.2019.06.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
42 Hossain F, Majumder S, David J, Miele L. Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions. Cancers (Basel) 2021;13:3739. [PMID: 34359640 DOI: 10.3390/cancers13153739] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 VanKlompenberg MK, Leyden E, Arnason AH, Zhang JT, Stefanski CD, Prosperi JR. APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation. Oncotarget 2017;8:102868-79. [PMID: 29262529 DOI: 10.18632/oncotarget.22263] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
44 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
45 Yang X, Shi Z, Zhang N, Ou Z, Fu S, Hu X, Shen Z. Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells. Cancer Cell Int 2014;14:107. [PMID: 25729327 DOI: 10.1186/s12935-014-0107-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
46 Park HS, Lee JD, Kim JY, Park S, Kim JH, Han HJ, Choi YA, Choi AR, Sohn JH, Kim SI. Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models. PLoS One 2019;14:e0225082. [PMID: 31821346 DOI: 10.1371/journal.pone.0225082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
47 VanKlompenberg MK, Bedalov CO, Soto KF, Prosperi JR. APC selectively mediates response to chemotherapeutic agents in breast cancer. BMC Cancer 2015;15:457. [PMID: 26049416 DOI: 10.1186/s12885-015-1456-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
48 Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME; Platinum Study Group. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 2014;106:dju044. [PMID: 24623533 DOI: 10.1093/jnci/dju044] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 9.0] [Reference Citation Analysis]
49 Chen D, Ma Y, Li P, Liu M, Fang Y, Zhang J, Zhang B, Hui Y, Yin Y. Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer. Molecules 2019;24:E2338. [PMID: 31242627 DOI: 10.3390/molecules24122338] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
50 Sales ME, Español AJ, Salem AR, Pulido PM, Sanchez Y, Sanchez F. Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy. Curr Clin Pharmacol 2019;14:91-100. [PMID: 30501602 DOI: 10.2174/1574884714666181203095437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
51 Afifi TH, Okasha RM, Ahmed HEA, Ilaš J, Saleh T, Abd-El-Aziz AS. Structure-activity relationships and molecular docking studies of chromene and chromene based azo chromophores: A novel series of potent antimicrobial and anticancer agents. EXCLI J 2017;16:868-902. [PMID: 28828001 DOI: 10.17179/excli2017-356] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
52 Kołacińska A, Chałubińska J, Błasińska-Morawiec M, Dowgier-Witczak I, Fendler W, Kordek R, Morawiec Z. Pathological complete response in younger and older breast cancer patients. Arch Med Sci 2012;8:310-5. [PMID: 22662005 DOI: 10.5114/aoms.2012.28559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
53 Balanis N, Carlin CR. Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer. Mol Cell Endocrinol 2017;451:24-30. [PMID: 28088463 DOI: 10.1016/j.mce.2017.01.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
54 Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013;31:2586-92. [PMID: 23733761 DOI: 10.1200/JCO.2012.46.2408] [Cited by in Crossref: 219] [Cited by in F6Publishing: 133] [Article Influence: 27.4] [Reference Citation Analysis]
55 Yaari Z, da Silva D, Zinger A, Goldman E, Kajal A, Tshuva R, Barak E, Dahan N, Hershkovitz D, Goldfeder M, Roitman JS, Schroeder A. Theranostic barcoded nanoparticles for personalized cancer medicine. Nat Commun 2016;7:13325. [PMID: 27830705 DOI: 10.1038/ncomms13325] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 15.4] [Reference Citation Analysis]
56 Chernikova SB, Nguyen RB, Truong JT, Mello SS, Stafford JH, Hay MP, Olson A, Solow-Cordero DE, Wood DJ, Henry S, von Eyben R, Deng L, Gephart MH, Aroumougame A, Wiese C, Game JC, Győrffy B, Brown JM. Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. J Clin Invest 2018;128:5307-21. [PMID: 30371505 DOI: 10.1172/JCI87191] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
57 Goldman A. Tailoring combinatorial cancer therapies to target the origins of adaptive resistance. Mol Cell Oncol 2016;3:e1030534. [PMID: 27308546 DOI: 10.1080/23723556.2015.1030534] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
58 Zhang YJ, Zhan X, Wang L, Ho RJ, Sasaki T. pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model. J Pharm Sci 2015;104:1815-24. [PMID: 25753991 DOI: 10.1002/jps.24407] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
59 Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov 2017;7:391-9. [PMID: 28255083 DOI: 10.1158/2159-8290.CD-16-0611] [Cited by in Crossref: 83] [Cited by in F6Publishing: 57] [Article Influence: 20.8] [Reference Citation Analysis]
60 Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Qin A, Oster G. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer 2011;11:250. [PMID: 21676243 DOI: 10.1186/1471-2407-11-250] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
61 Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 2012;4:511-20. [PMID: 23071421 DOI: 10.2147/IJWH.S18541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 47] [Article Influence: 1.9] [Reference Citation Analysis]
62 Sapio L, Sorvillo L, Illiano M, Chiosi E, Spina A and Naviglio S. Inorganic phosphate prevents Erk1/2 and Stat3 activation and improves sensitivity to doxorubicin of MDA-MB-231 breast cancer cells. Molecules. 2015;20:15910-15928. [PMID: 26340617 DOI: 10.3390/molecules200915910] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
63 Oudin MJ, Barbier L, Schäfer C, Kosciuk T, Miller MA, Han S, Jonas O, Lauffenburger DA, Gertler FB. MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer. Mol Cancer Ther 2017;16:143-55. [PMID: 27811011 DOI: 10.1158/1535-7163.MCT-16-0413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
64 Zhen Y, Zhang Y, Yu Y. A Cell-Line-Specific Atlas of PARP-Mediated Protein Asp/Glu-ADP-Ribosylation in Breast Cancer. Cell Rep 2017;21:2326-37. [PMID: 29166620 DOI: 10.1016/j.celrep.2017.10.106] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
65 Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci 2012;13:14898-916. [PMID: 23203101 DOI: 10.3390/ijms131114898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
66 Dandawate PR, Subramaniam D, Jensen RA, Anant S. Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy. Semin Cancer Biol 2016;40-41:192-208. [PMID: 27609747 DOI: 10.1016/j.semcancer.2016.09.001] [Cited by in Crossref: 110] [Cited by in F6Publishing: 112] [Article Influence: 22.0] [Reference Citation Analysis]
67 Doddapaneni R, Patel K, Chowdhury N, Singh M. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Exp Cell Res 2016;346:65-73. [PMID: 27177833 DOI: 10.1016/j.yexcr.2016.05.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
68 Miller-Kleinhenz JM, Bozeman EN, Yang L. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2015;7:797-816. [PMID: 25966677 DOI: 10.1002/wnan.1343] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
69 Soung YH, Pruitt K, Chung J. Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells. Sci Rep 2014;4:3846. [PMID: 24457910 DOI: 10.1038/srep03846] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
70 Medina MA, Oza G, Sharma A, Arriaga LG, Hernández Hernández JM, Rotello VM, Ramirez JT. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health 2020;17:E2078. [PMID: 32245065 DOI: 10.3390/ijerph17062078] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 24.0] [Reference Citation Analysis]
71 Schouten PC, Dackus GM, Marchetti S, van Tinteren H, Sonke GS, Schellens JH, Linn SC. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Trials 2016;17:293. [PMID: 27323902 DOI: 10.1186/s13063-016-1423-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
72 Keetile NM, Osuch E, Lentoor AG. Chemotherapy-related subjective cognitive impairment in breast cancer patients in semi-rural South Africa. Health SA 2021;26:1605. [PMID: 34394969 DOI: 10.4102/hsag.v26i0.1605] [Reference Citation Analysis]
73 Peng F, Xiong L, Xie X, Tang H, Huang R, Peng C. Isoliquiritigenin Derivative Regulates miR-374a/BAX Axis to Suppress Triple-Negative Breast Cancer Tumorigenesis and Development. Front Pharmacol 2020;11:378. [PMID: 32296334 DOI: 10.3389/fphar.2020.00378] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
74 Ruddarraju RR, Murugulla AC, Kotla R, Tirumalasetty MCB, Wudayagiri R, Donthabakthuni S, Maroju R. Design, synthesis, anticancer activity and docking studies of theophylline containing 1,2,3-triazoles with variant amide derivatives. Medchemcomm 2017;8:176-83. [PMID: 30108703 DOI: 10.1039/c6md00479b] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 4.6] [Reference Citation Analysis]
75 Emma MR, Augello G, Di Stefano V, Azzolina A, Giannitrapani L, Montalto G, Cervello M, Cusimano A. Potential Uses of Olive Oil Secoiridoids for the Prevention and Treatment of Cancer: A Narrative Review of Preclinical Studies. Int J Mol Sci 2021;22:1234. [PMID: 33513799 DOI: 10.3390/ijms22031234] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
76 Uddin MH, Pimentel JM, Chatterjee M, Allen JE, Zhuang Z, Wu GS. Targeting PP2A inhibits the growth of triple-negative breast cancer cells. Cell Cycle 2020;19:592-600. [PMID: 32011210 DOI: 10.1080/15384101.2020.1723195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Banik U, Parasuraman S, Adhikary AK, Othman NH. Curcumin: the spicy modulator of breast carcinogenesis. J Exp Clin Cancer Res 2017;36:98. [PMID: 28724427 DOI: 10.1186/s13046-017-0566-5] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 16.3] [Reference Citation Analysis]
78 Toft DJ, Cryns VL. Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol 2011;25:199-211. [PMID: 20861225 DOI: 10.1210/me.2010-0164] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 8.6] [Reference Citation Analysis]
79 Khaw-On P, Pompimon W, Banjerdpongchai R. Apoptosis Induction via ATM Phosphorylation, Cell Cycle Arrest, and ER Stress by Goniothalamin and Chemodrugs Combined Effects on Breast Cancer-Derived MDA-MB-231 Cells. Biomed Res Int 2018;2018:7049053. [PMID: 30598998 DOI: 10.1155/2018/7049053] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
80 Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014;5:1174-1184. [PMID: 24632568 DOI: 10.18632/oncotarget.1682] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 17.2] [Reference Citation Analysis]
81 Wu Q, Siddharth S, Sharma D. Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs. Cancers (Basel) 2021;13:3697. [PMID: 34359598 DOI: 10.3390/cancers13153697] [Reference Citation Analysis]
82 Guo Y, Fan Y, Pei X. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model. Cancer Med 2020;9:2564-78. [PMID: 32037729 DOI: 10.1002/cam4.2894] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
83 Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS, Samli B, Jansen RJ, Petricoin EF, Goetz MP, Bear HD, Tang AH. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers (Basel) 2020;12:E2392. [PMID: 32846967 DOI: 10.3390/cancers12092392] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 23.0] [Reference Citation Analysis]
84 Cañedo EC, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, Autexier C, Deblois G, Park M, Witcher M, Ursini-Siegel J. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors. JCI Insight 2021;6:138382. [PMID: 33470989 DOI: 10.1172/jci.insight.138382] [Reference Citation Analysis]
85 Deepak Singh D, Han I, Choi EH, Yadav DK. CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer. Comput Struct Biotechnol J 2021;19:2384-97. [PMID: 34025931 DOI: 10.1016/j.csbj.2021.04.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Ou YC, Webb JA, Faley S, Shae D, Talbert EM, Lin S, Cutright CC, Wilson JT, Bellan LM, Bardhan R. Gold Nanoantenna-Mediated Photothermal Drug Delivery from Thermosensitive Liposomes in Breast Cancer. ACS Omega 2016;1:234-43. [PMID: 27656689 DOI: 10.1021/acsomega.6b00079] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
87 He DX, Gu F, Gao F, Hao JJ, Gong D, Gu XT, Mao AQ, Jin J, Fu L, Ma X. Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer. Sci Rep 2016;6:24706. [PMID: 27094684 DOI: 10.1038/srep24706] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
88 Philipovskiy A, Dwivedi AK, Gamez R, McCallum R, Mukherjee D, Nahleh Z, Aguilera RJ, Gaur S. Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer. PLoS One 2020;15:e0238262. [PMID: 32886682 DOI: 10.1371/journal.pone.0238262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
89 Wang H, Milberg O, Bartelink IH, Vicini P, Wang B, Narwal R, Roskos L, Santa-Maria CA, Popel AS. In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. R Soc Open Sci 2019;6:190366. [PMID: 31218069 DOI: 10.1098/rsos.190366] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
90 Lakshmaiah KC, Anand A, Babu KG, Dasappa L, Jacob LA, Babu M C S, Lokesh KN, Rudresha AH, Rajeev LK, Saldanha SC, Giri GV, Koppaka D. Role of Taxanes in Triple-Negative Breast Cancer: A Study From Tertiary Cancer Center in South India. World J Oncol 2017;8:110-6. [PMID: 29147445 DOI: 10.14740/wjon1054w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
91 Varghese E, Samuel SM, Abotaleb M, Cheema S, Mamtani R, Büsselberg D. The "Yin and Yang" of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers. Cancers (Basel) 2018;10:E346. [PMID: 30248941 DOI: 10.3390/cancers10100346] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
92 Donovan MG, Selmin OI, Stillwater BJ, Neumayer LA, Romagnolo DF. Do Olive and Fish Oils of the Mediterranean Diet Have a Role in Triple Negative Breast Cancer Prevention and Therapy? An Exploration of Evidence in Cells and Animal Models. Front Nutr 2020;7:571455. [PMID: 33123546 DOI: 10.3389/fnut.2020.571455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
93 Feng W, Li Y, Chu J, Li J, Zhang Y, Ding X, Fu Z, Li W, Huang X, Yin Y. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer. Cancer Med 2018;7:5130-44. [PMID: 30239174 DOI: 10.1002/cam4.1761] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
94 Wu X, Tang P, Li S, Wang S, Liang Y, Zhong L, Ren L, Zhang T, Zhang Y. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. Nat Commun 2018;9:832. [PMID: 29483583 DOI: 10.1038/s41467-018-03210-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
95 Wani TH, Chowdhury G, Chakrabarty A. Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155). RSC Med Chem 2021;12:566-78. [PMID: 34046628 DOI: 10.1039/d0md00383b] [Reference Citation Analysis]
96 Carneiro TJ, Araújo R, Vojtek M, Gonçalves-Monteiro S, de Carvalho ALMB, Marques MPM, Diniz C, Gil AM. Impact of the Pd2Spm (Spermine) Complex on the Metabolism of Triple-Negative Breast Cancer Tumors of a Xenograft Mouse Model. Int J Mol Sci 2021;22:10775. [PMID: 34639114 DOI: 10.3390/ijms221910775] [Reference Citation Analysis]
97 Pal S, Lüchtenborg M, Davies EA, Jack RH. The treatment and survival of patients with triple negative breast cancer in a London population. Springerplus 2014;3:553. [PMID: 25324980 DOI: 10.1186/2193-1801-3-553] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
98 Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015;33:1902-1909. [PMID: 25847936 DOI: 10.1200/jco.2014.57.6660] [Cited by in Crossref: 237] [Cited by in F6Publishing: 130] [Article Influence: 39.5] [Reference Citation Analysis]
99 Hu MH, Wu TY, Huang Q, Jin G. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription. Nucleic Acids Res 2019;47:10529-42. [PMID: 31584090 DOI: 10.1093/nar/gkz835] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 29.0] [Reference Citation Analysis]
100 Bodenstine TM, Chandler GS, Reed DW, Margaryan NV, Gilgur A, Atkinson J, Ahmed N, Hyser M, Seftor EA, Strizzi L, Hendrix MJ. Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment. Cell Cycle 2016;15:1295-302. [PMID: 27007464 DOI: 10.1080/15384101.2016.1160981] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
101 Li R, Chen J, Gao X, Jiang G. Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1. Cancer Biol Ther 2021;22:465-77. [PMID: 34486497 DOI: 10.1080/15384047.2021.1949228] [Reference Citation Analysis]
102 Lee Y, Kim H, Kim H, Cho HY, Jee JG, Seo KA, Son JB, Ko E, Choi HG, Kim ND, Kim I. X-ray Crystal Structure-Guided Design and Optimization of 7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile Scaffold as a Potent and Orally Active Monopolar Spindle 1 Inhibitor. J Med Chem 2021;64:6985-95. [PMID: 33942608 DOI: 10.1021/acs.jmedchem.1c00542] [Reference Citation Analysis]
103 Syed BM, Morgan D, Setty T, Green AR, Paish EC, Ellis IO, Cheung KL. Oestrogen receptor negative early operable primary breast cancer in older women-Biological characteristics and long-term clinical outcome. PLoS One 2017;12:e0188528. [PMID: 29284000 DOI: 10.1371/journal.pone.0188528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Sun S, Wu H, Wu X, You Z, Jiang Y, Liang X, Chen Z, Zhang Y, Wei W, Jiang Y, Chen Y, Song Y, Pang D. Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer. Front Oncol 2021;11:535230. [PMID: 33747900 DOI: 10.3389/fonc.2021.535230] [Reference Citation Analysis]
105 Bowerman CJ, Byrne JD, Chu KS, Schorzman AN, Keeler AW, Sherwood CA, Perry JL, Luft JC, Darr DB, Deal AM, Napier ME, Zamboni WC, Sharpless NE, Perou CM, DeSimone JM. Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. Nano Lett 2017;17:242-8. [PMID: 27966988 DOI: 10.1021/acs.nanolett.6b03971] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 9.6] [Reference Citation Analysis]
106 Gao G, Wang Z, Qu X, Zhang Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer 2020;20:179. [PMID: 32131780 DOI: 10.1186/s12885-020-6668-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 31.0] [Reference Citation Analysis]
107 Bittner AK, Keup C, Hoffmann O, Hauch S, Kimmig R, Kasimir-Bauer S. Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients. J Cell Mol Med 2020;24:8405-16. [PMID: 32558176 DOI: 10.1111/jcmm.15349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
108 Tiwary R, Yu W, Sanders BG, Kline K. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. Breast Cancer Res 2011;13:R1. [PMID: 21214929 DOI: 10.1186/bcr2801] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
109 Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P, Shu D. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. Mol Ther 2019;27:1252-61. [PMID: 31085078 DOI: 10.1016/j.ymthe.2019.04.018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 21.5] [Reference Citation Analysis]
110 Subramaniam D, Ramalingam S, Houchen CW, Anant S. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev Med Chem 2010;10:359-71. [PMID: 20370703 DOI: 10.2174/138955710791330954] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 5.8] [Reference Citation Analysis]
111 Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncol Lett 2014;7:866-70. [PMID: 24527094 DOI: 10.3892/ol.2014.1782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]